Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2009

Open Access 01-12-2009 | Research article

Systematic review of pharmacological treatments in fragile X syndrome

Authors: Jose-Ramon Rueda, Javier Ballesteros, Maria-Isabel Tejada

Published in: BMC Neurology | Issue 1/2009

Login to get access

Abstract

Background

Fragile X syndrome (FXS) is considered the most common cause of inherited mental retardation. Affected people have mental impairment that can include Attention Deficit and/or Hyperactivity Disorder (ADHD), autism disorder, and speech and behavioural disorders. Several pharmacological interventions have been proposed to treat those impairments.

Methods

Systematic review of the literature and summary of the evidence from clinical controlled trials that compared at least one pharmacological treatment with placebo or other treatment in individuals with diagnosis of FXS syndrome and assessed the efficacy and/or safety of the treatments. Studies were identified by a search of PubMed, EMBASE and the Cochrane Databases using the terms fragile X and treatment. Risk of bias of the studies was assessed by using the Cochrane Collaboration criteria.

Results

The search identified 276 potential articles and 14 studies satisfied inclusion criteria. Of these, 10 studies on folic acid (9 with crossover design, only 1 of them with good methodological quality and low risk of bias) did not find in general significant improvements. A small sample size trial assessed dextroamphetamine and methylphenidate in patients with an additional diagnosis of ADHD and found some improvements in those taking methylphenidate, but the length of follow-up was too short. Two studies on L-acetylcarnitine, showed positive effects and no side effects in patients with an additional diagnosis of ADHD. Finally, one study on patients with an additional diagnosis of autism assessed ampakine compound CX516 and found no significant differences between treatment and placebo. Regarding safety, none of the studies that assessed that area found relevant side effects, but the number of patients included was too small to detect side effects with low incidence.

Conclusion

Currently there is no robust evidence to support recommendations on pharmacological treatments in patients with FXS in general or in those with an additional diagnosis of ADHD or autism.
Appendix
Available only for authorised users
Literature
1.
Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991, 65: 905-914. 10.1016/0092-8674(91)90397-H.CrossRefPubMed
2.
3.
4.
Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A: a literature review and modelling study. Health Technol Assess. 2003, 7: 1-106.CrossRef
5.
Hagerman RJ, Murphy MA, Wittenberger MD: A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988, 30: 377-392. 10.1002/ajmg.1320300138.CrossRefPubMed
6.
7.
Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ: Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord. 2007, 37: 738-747. 10.1007/s10803-006-0205-z.CrossRefPubMed
8.
Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman RJ: Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008, 113: 427-438. 10.1352/2008.113:427-438.CrossRefPubMed
9.
Bear MF: Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005, 4: 393-398. 10.1111/j.1601-183X.2005.00135.x.CrossRefPubMed
10.
Cornish K, Turk J, Hagerman R: The fragile X continuum: new advances and perspectives. J Intellect Disabil Res. 2008, 52: 469-482. 10.1111/j.1365-2788.2008.01056.x.CrossRefPubMed
11.
Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M: Advances in the treatment of fragile X syndrome. Pediatrics. 2009, 123: 378-390. 10.1542/peds.2008-0317.CrossRefPubMedPubMedCentral
12.
Berry-Kravis E, Potanos K: Psychopharmacology in fragile X syndrome. Present and future. MRDD Research Reviews. 2004, 10: 42-48.
13.
Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D'Iddio S, Calvani M, Neri G: A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008, 146: 803-812.CrossRef
14.
Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R: Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006, 16: 525-540. 10.1089/cap.2006.16.525.CrossRefPubMed
15.
Reiss AL, Hall SS: Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am. 2007, 16: 663-675. 10.1016/j.chc.2007.03.001.CrossRefPubMed
16.
Valdovinos MG: Brief review of current research in FXS: implications for treatment with psychotropic medication. Res Dev Disabil. 2007, 28: 539-545. 10.1016/j.ridd.2006.09.001.CrossRefPubMed
17.
Higgins JPT, Altman DG: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions. Cochrane Book Series. Edited by: Higgins JPTGS. 2008, Chichester, John Wiley and Sons Inc, 187-241.CrossRef
18.
Hagerman RJ, McBogg P, Levitas A, McGravran L, Smith ACM, Berry R, Braden M, Van Norman K, Newall K, Matus I: Folic acid treatment of the fragile X syndrome. Am J Med Genet. 1983, 35 (274): Abstract 92A
19.
Cohen IL, Tsiouris JA, Pfadt A: Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 1991, 11: 398-399.PubMed
20.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg. 2000, 87: 1448-1454. 10.1046/j.1365-2168.2000.01610.x.CrossRefPubMed
21.
Brown WT, Jenkins EC, Friedman E, Brooks J, Cohen IL, Duncan C, Hill AL, Malik MN, Morris V, Wolf E: Folic acid therapy in the fragile X syndrome. Am J Med Genet. 1984, 17: 289-297. 10.1002/ajmg.1320170121.CrossRefPubMed
22.
Brown WT, Cohen IL, Fisch GS, Wolf-Schein EG, Jenkins VA, Malik MN, Jenkins EC: High dose folic acid treatment of fragile X males. Am J Med Genet. 1986, 23: 263-271. 10.1002/ajmg.1320230120.CrossRefPubMed
23.
Carpenter NJ, Barber DH, Jones M, Lindley W, Carr C: Controlled six-month study of oral folic acid therapy in boys with fragile X-linked mental retardation. Am J Med Genet. 1983, 35 (243): 82A-
24.
Fisch GS, Cohen IL, Gross AC, Jenkins V, Jenkins EC, Brown WT: Folic acid treatment of fragile X males: a further study. Am J Med Genet. 1988, 30: 393-399. 10.1002/ajmg.1320300139.CrossRefPubMed
25.
Hagerman RJ, Jackson AW, Levitas A, Braden M, McBogg P, Kemper M, McGavran L, Berry R, Matus I, Hagerman PJ: Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet. 1986, 23: 241-262. 10.1002/ajmg.1320230119.CrossRefPubMed
26.
Madison LS, Wells TE, Fristo TE, Benesch CG: A controlled study of folic acid treatment in three fragile X syndrome males. J Dev Behav Pediatr. 1986, 7: 253-256. 10.1097/00004703-198608000-00007.CrossRefPubMed
27.
Strom CM, Brusca RM, Pizzi WJ: Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet. 1992, 44: 676-682. 10.1002/ajmg.1320440529.CrossRefPubMed
28.
Rosenblatt DS, Duschenes EA, Hellstrom FV, Golick MS, Vekemans MJ, Zeesman SF, Andermann E: Folic acid blinded trial in identical twins with fragile X syndrome. Am J Hum Genet. 1985, 37: 543-552.PubMedPubMedCentral
29.
Froster-Iskenius U, Bodeker K, Oepen T, Matthes R, Piper U, Schwinger E: Folic acid treatment in males and females with fragile X syndrome. Am J Med Genet. 1986, 23: 273-289. 10.1002/ajmg.1320230121.CrossRefPubMed
30.
Gillberg C, Wahlstrom J, Johansson R, Tornblom M, bertsson-Wikland K: Folic acid as an adjunct in the treatment of children with the autism fragile X syndrome (AFRAX). Dev Med Child Neurol. 1986, 28: 624-627.CrossRefPubMed
31.
Zarcone JR, Napolitano DA, Valdovinos MG: Measurement of problem behaviour during medication evaluations. J Intellect Disabil Res. 2008, 52: 1015-1028. 10.1111/j.1365-2788.2008.01109.x.CrossRefPubMed
32.
Torrioli MG, Vernacotola S, Mariotti P, Bianchi E, Calvani M, de GA, Chiurazzi P, Neri G: Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet. 1999, 87: 366-368. 10.1002/(SICI)1096-8628(19991203)87:4<366::AID-AJMG18>3.0.CO;2-F.CrossRefPubMed
33.
Brodkin ES: Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. Behav Neurosci. 2008, 122: 483-489. 10.1037/0735-7044.122.2.483.CrossRefPubMed
34.
Moher D, Schulz KF, Altman DG, CONSORT GROUP Consolidated Standards of Reporting Trials): The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001, 134: 657-662.CrossRefPubMed
35.
Higgins JPT, Deeks JJ, Altman DG: Special topics in statistics. Cochrane handbook for systematic reviews of interventions. Edited by: Higgins JPTGS. 2008, Chichester, John Wiley and Sons Inc, 481-529.CrossRef
36.
Berry-Kravis E, Sumis A, Kim OK, Lara R, Wuu J: Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord. 2008, 38: 1751-1757. 10.1007/s10803-008-0564-8.CrossRefPubMed
37.
Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT: Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008, 29: 293-302. 10.1097/DBP.0b013e31817dc447.CrossRefPubMed
38.
Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman RJ: A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009, 46: 266-271. 10.1136/jmg.2008.063701.CrossRefPubMedPubMedCentral
39.
Kesler SR, Lightbody AA, Reiss AL: Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A. 2009, 149 (A): 403-407.CrossRef
40.
Erickson CA, Mullett JE, McDougle CJ: Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009,
41.
Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM: Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009, 46: 94-102. 10.1136/jmg.2008.061796.CrossRefPubMed
42.
de Diego-Otero Y, Romero-Zerbo Y, el BR, Decara J, Sanchez L, Rodriguez-de FF, del Arco-Herrera I: Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology. 2009, 34: 1011-1026. 10.1038/npp.2008.152.CrossRefPubMed
43.
Romero-Zerbo Y, Decara J, el Bekay R, Sanchez-Salido L, Del Arco-Herrera I, de Fonseca FR, de Diego-Otero Y: Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res. 2009, 46: 224-234. 10.1111/j.1600-079X.2008.00653.x.CrossRefPubMed
44.
Hall SS, DeBernardis GM, Reiss AL: The acquisition of stimulus equivalence in individuals with fragile X syndrome. J Intellect Disabil Res. 2006, 50: 643-651. 10.1111/j.1365-2788.2006.00814.x.CrossRefPubMed
45.
Hall SS, Maynes NP, Reiss AL: Using percentile schedules to increase eye contact in children with fragile X syndrome. J Applied Behav Analysis. 2009, 42: 171-176. 10.1901/jaba.2009.42-171.CrossRef
46.
Weiskop S, Richdale A, Matthews J: Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurology. 2005, 47: 94-104. 10.1017/S0012162205000186.CrossRef
Metadata
Title
Systematic review of pharmacological treatments in fragile X syndrome
Authors
Jose-Ramon Rueda
Javier Ballesteros
Maria-Isabel Tejada
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2009
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-9-53

Other articles of this Issue 1/2009

BMC Neurology 1/2009 Go to the issue

Research article

Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen

Research article

SPEM dysfunction and general schizotypy as measured by the SSQ: a controlled study

Research article

Clinical presentation and diffusion weighted MRI of acute cerebral infarction. The Bergen Stroke Study

Research article

Functional polymorphisms in matrix metalloproteinases -1, -3, -9 and -12 in relation to cervical artery dissection

Study protocol

Cardiac rehabilitation adapted to transient ischaemic attack and stroke (CRAFTS): a randomised controlled trial

Research article

Infarction in the territory of the anterior cerebral artery: clinical study of 51 patients